HAP Trading’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

HAP Trading’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-18,000	Closed	-$22K	–	2563
2022 Q1	$22K	Sell	18,000 -2,000	-10%	-$249K	﹤0.01%	1533
2021 Q4	$363K	Buy	+20,000	New	+$2.54M	0.01%	804
2021 Q1	–	Sell	-234,500	Closed	-$2.77M	–	2792
2020 Q4	$2.77M	Buy	234,500 +62,600	+36%	+$5.3M	0.08%	211
2020 Q3	$739K	Buy	171,900 +21,800	+15%	+$1.43M	0.04%	322
2020 Q2	$2.08M	Buy	150,100 +58,000	+63%	+$3.09M	0.11%	150
2020 Q1	$17K	Buy	92,100 +19,400	+27%	+$887K	﹤0.01%	954
2019 Q4	$77K	Sell	72,700 -146,400	-67%	-$7.25M	﹤0.01%	617
2019 Q3	$204K	Sell	219,100 -29,400	-12%	-$1.24M	0.02%	495
2019 Q2	$748K	Buy	248,500 +225,800	+995%	+$12.7M	0.06%	265
2019 Q1	$91K	Buy	+22,700	New	+$981K	0.01%	563

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HAP Trading's BHVN Position: Q1 2020 in Review

HAP Trading sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2020, closing a stake of 91,752 shares — an estimated $4.2M sold.

HAP Trading first reported a position in BHVN in Q1 2018 and held it in 3 quarters. The position peaked at $5M in Q4 2019. 175 funds tracked by Wall St. Rank hold BHVN as of Q1 2020.

HAP Trading reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q1 2020 after selling out during the quarter.
HAP Trading sold 91,752 Biohaven Pharmaceutical Holding Company Ltd. shares in Q1 2020, an estimated $4.2M.
HAP Trading first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018 and held it in 3 quarters.
HAP Trading's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $5M in Q4 2019.
175 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2020.

Based on HAP Trading's 13F filing for Q1 2020, filed 8 May 2020.